Physician profile
Armando Jarquin
NPI 1326043860
$2,195.02
in general payments reported to CMS, 2019-2025
14 companies · $633 in 2025
The $633 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $112 · 2022: $237 · 2023: $478 · 2024: $248 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $275.32 | 2022-2025 | Spinraza, Spinraza |
| Alnylam Pharmaceuticals INC. | $258.54 | 2024-2025 | Amvuttra |
| Novo Nordisk INC | $240.96 | 2019-2023 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $234.02 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $221.56 | 2019 | |
| Sanofi-Aventis U.S. LLC | $150.00 | 2025 | |
| Abbott Laboratories | $141.80 | 2022 | |
| Genzyme Corporation | $124.97 | 2025 | |
| Inspire Medical Systems, INC. | $122.54 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $122.52 | 2024 | Airsupra |
| Glaxosmithkline, LLC. | $101.52 | 2023 | Bexsero |
| Pharming Healthcare, INC. | $93.98 | 2023 | Ruconest |
| Medtronic, INC. | $89.57 | 2023 | Corevalve Evolut R |
| Intra-Sana Laboratories | $17.72 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armando Jarquin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.